ATOSSA THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

19 3 2024 09:49:14 提供 NetDania Notify

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

19 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

18 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

12 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

06 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

22 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

07 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Issues Letter to Shareholders

09 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

04 12 2023 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

20 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

13 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

09 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

18 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

14 8 2023 07:30:03 提供 Nasdaq GlobeNewswire

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

08 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

20 7 2023 08:15:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

13 7 2023 15:15:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

10 7 2023 08:15:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

06 7 2023 08:15:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

28 6 2023 08:15:00 提供 Nasdaq GlobeNewswire